Figure 1.
Figure 1. Epo profiles obtained by double immunoblotting. (A) Acceptance criteria for rhEpo, as defined by WADA.1 (B) Figure 1A from Beullens et al.2 Lane 1, epoetin β; lane 2, darbepoietin α; lane 3, “false-positive” urine sample collected immediately after exercise; lane 4, negative urine sample collected 1 hour after the sample in lane 3. (C) Figure 1 from Lasne. Lane 5, mixture of epoetin β and darbepoietin α; lane 6, urine sample after strenuous exercise; lane 7, natural urinary Epo; lane 8, urine sample showing protein P, unrelated to Epo; lane 9, urine sample in case of epoetin administration. Bands in panels B and C are numbered according to the criteria defined in panel A. Using the acceptance criteria of panel A, lanes 3 (panel B), 6, and 9 (panel C) should be considered as an adverse analytical finding corresponding to the presence of rhEpo.

Epo profiles obtained by double immunoblotting. (A) Acceptance criteria for rhEpo, as defined by WADA. (B) Figure 1A from Beullens et al. Lane 1, epoetin β; lane 2, darbepoietin α; lane 3, “false-positive” urine sample collected immediately after exercise; lane 4, negative urine sample collected 1 hour after the sample in lane 3. (C) Figure 1 from Lasne. Lane 5, mixture of epoetin β and darbepoietin α; lane 6, urine sample after strenuous exercise; lane 7, natural urinary Epo; lane 8, urine sample showing protein P, unrelated to Epo; lane 9, urine sample in case of epoetin administration. Bands in panels B and C are numbered according to the criteria defined in panel A. Using the acceptance criteria of panel A, lanes 3 (panel B), 6, and 9 (panel C) should be considered as an adverse analytical finding corresponding to the presence of rhEpo.

Close Modal

or Create an Account

Close Modal
Close Modal